Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:ARVNNASDAQ:CGONNASDAQ:CNTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$37.38+4.2%$25.85$16.50▼$37.95$3.26BN/A12,996 shs25,208 shsARVNArvinas$7.44-0.4%$7.46$5.90▼$34.11$543.05M2.21.44 million shs2.15 million shsCGONCG Oncology$25.55-2.8%$24.87$14.80▼$40.47$1.95B0.87837,471 shs987,475 shsCNTACentessa Pharmaceuticals$12.43-2.0%$12.70$8.46▼$19.09$1.66B1.48719,890 shs1.61 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International0.00%+18.63%+41.16%+97.05%+3,737,999,900.00%ARVNArvinas0.00%+0.68%+14.29%-13.59%-70.50%CGONCG Oncology0.00%-1.20%+0.43%-10.45%-18.71%CNTACentessa Pharmaceuticals0.00%+0.40%-3.42%-25.26%+36.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AARVNArvinas3.7343 of 5 stars4.34.00.00.02.31.71.3CGONCG Oncology2.1974 of 5 stars4.51.00.00.01.90.80.0CNTACentessa Pharmaceuticals3.4997 of 5 stars4.52.00.00.02.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AARVNArvinas 2.55Moderate Buy$20.29172.71% UpsideCGONCG Oncology 3.00Buy$58.67129.62% UpsideCNTACentessa Pharmaceuticals 3.00Buy$27.89124.37% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, CNTA, AAPG, and CGON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$52.00 ➝ $56.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/28/2025CNTACentessa PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.005/19/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.005/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.50(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M24.24N/AN/A$0.48 per share77.88ARVNArvinas$263.40M2.06N/AN/A$8.17 per share0.91CGONCG Oncology$1.14M1,708.26N/AN/A$9.63 per share2.65CNTACentessa Pharmaceuticals$6.85M242.34N/AN/A$3.05 per share4.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/AARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)CGONCG Oncology-$88.04M-$1.51N/AN/AN/A-15,945.17%-16.71%-16.24%8/14/2025 (Estimated)CNTACentessa Pharmaceuticals-$235.76M-$1.81N/AN/AN/AN/A-40.22%-29.95%8/12/2025 (Estimated)Latest ARVN, CNTA, AAPG, and CGON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CGONCG Oncology-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A3/25/2025Q4 2024CGONCG Oncology-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 million3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26ARVNArvinasN/A4.584.58CGONCG OncologyN/A30.9730.97CNTACentessa Pharmaceuticals0.2814.3714.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AARVNArvinas95.19%CGONCG Oncology26.56%CNTACentessa Pharmaceuticals82.01%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AARVNArvinas4.73%CGONCG OncologyN/ACNTACentessa Pharmaceuticals7.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/AARVNArvinas42072.99 million69.54 millionOptionableCGONCG Oncology6176.22 millionN/AOptionableCNTACentessa Pharmaceuticals200133.55 million124.09 millionOptionableARVN, CNTA, AAPG, and CGON HeadlinesRecent News About These CompaniesCentessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Sells $694,650.00 in StockJune 21 at 6:16 AM | insidertrades.comCentessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Buy" by AnalystsJune 21 at 2:19 AM | marketbeat.comSaurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) StockJune 20 at 11:45 PM | marketbeat.comCentessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep ...June 18, 2025 | seekingalpha.comCentessa announces clearance of IND for ORX142June 18, 2025 | finance.yahoo.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Bought by GAMMA Investing LLCJune 17, 2025 | marketbeat.comCentessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?June 16, 2025 | zacks.comCentessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this YearJune 16, 2025 | globenewswire.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Stake Decreased by Two Sigma Investments LPJune 9, 2025 | marketbeat.comBank of America Corp DE Has $732,000 Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)June 9, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 9.5% - Should You Sell?June 5, 2025 | marketbeat.comWall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a BetJune 4, 2025 | zacks.comCentessa Pharmaceuticals Announces Executive ChangesMay 30, 2025 | investing.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 10,000 Shares of StockMay 29, 2025 | marketbeat.comNeedham Initiates Coverage of Centessa Pharmaceuticals plc - Depositary Receipt () (CNTA) with Buy RecommendationMay 29, 2025 | msn.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up - Should You Buy?May 29, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Needham & Company LLCMay 29, 2025 | marketbeat.comGregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockMay 28, 2025 | insidertrades.comMillennium Management LLC Raises Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)May 28, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Recommendation of "Buy" by AnalystsMay 28, 2025 | marketbeat.comWoodline Partners LP Buys 29,266 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)May 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, CNTA, AAPG, and CGON Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$37.38 +1.50 (+4.18%) As of 06/20/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Arvinas NASDAQ:ARVN$7.44 -0.03 (-0.40%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.40 -0.04 (-0.59%) As of 06/20/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.CG Oncology NASDAQ:CGON$25.55 -0.73 (-2.78%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$25.54 -0.02 (-0.06%) As of 06/20/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Centessa Pharmaceuticals NASDAQ:CNTA$12.43 -0.25 (-1.97%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$12.46 +0.03 (+0.24%) As of 06/20/2025 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
